Want to see CAPR full AI Analyst Report?
CAPR Analyst Ratings
Strong Buy
8 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
CAPR Stock 12 Month Forecast
Average Price Target
$53.00
▲(52.74% Upside)
| Highest Price Target$62.00 | Average Price Target$53.00 | Lowest Price Target$38.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
H.C. Wainwright
$60
Buy
72.91%
Upside
Reiterated
06/29/26
Oppenheimer
$54
Buy
55.62%
Upside
Reiterated
06/18/26
Roth MKM
$38
Buy
9.51%
Upside
Reiterated
05/29/26
Alliance Global Partners
$51
Buy
46.97%
Upside
Reiterated
05/14/26
JonesTrading
$51
Buy
46.97%
Upside
Reiterated
05/13/26
We discuss the nuances below, but the bottom line is that the US commercial agreement is not workable in its current form, and CAPR is seeking rescission after negotiations stalled. Despite initial negative stock reaction, we see this as a value-creation opportunity in the long run. Deramiocel is a multi- billion dollar opportunity in the US, and CAPR can likely launch the drug without a commercial partner. The best case scenario is that CAPR walks away from the deal, minus ~$50M in R&D payments previously received from NS Pharma.
Piper Sandler
$58
Buy
67.15%
Upside
Reiterated
05/13/26
Cantor Fitzgerald
$62
Buy
78.67%
Upside
Reiterated
05/12/26
Maxim Group
$50
Buy
44.09%
Upside
Reiterated
05/11/26
B. Riley Securities
$50→$63
Buy
81.56%
Upside
Assigned
03/13/26
Analyst Type
Any
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
H.C. Wainwright
$60
Buy
72.91%
Upside
Reiterated
06/29/26
Oppenheimer
$54
Buy
55.62%
Upside
Reiterated
06/18/26
Roth MKM
$38
Buy
9.51%
Upside
Reiterated
05/29/26
Alliance Global Partners
$51
Buy
46.97%
Upside
Reiterated
05/14/26
JonesTrading
$51
Buy
46.97%
Upside
Reiterated
05/13/26
We discuss the nuances below, but the bottom line is that the US commercial agreement is not workable in its current form, and CAPR is seeking rescission after negotiations stalled. Despite initial negative stock reaction, we see this as a value-creation opportunity in the long run. Deramiocel is a multi- billion dollar opportunity in the US, and CAPR can likely launch the drug without a commercial partner. The best case scenario is that CAPR walks away from the deal, minus ~$50M in R&D payments previously received from NS Pharma.
Piper Sandler
$58
Buy
67.15%
Upside
Reiterated
05/13/26
Cantor Fitzgerald
$62
Buy
78.67%
Upside
Reiterated
05/12/26
Maxim Group
$50
Buy
44.09%
Upside
Reiterated
05/11/26
B. Riley Securities
$50→$63
Buy
81.56%
Upside
Assigned
03/13/26
Best Analysts Covering Capricor Therapeutics
3 Months
Success Rate
5/12 ratings generated profit
Average Return
+33.98%
Copying Kristen Kluska's trades and holding each position for 3 Months would result in 41.67% of your transactions generating a profit, with an average return of +33.98% per trade.
1 Year
Success Rate
9/13 ratings generated profit
Average Return
+104.54%
Copying Jason McCarthy's trades and holding each position for 1 Year would result in 69.23% of your transactions generating a profit, with an average return of +104.54% per trade.
2 Years
Success Rate
9/11 ratings generated profit
Average Return
+99.16%
Copying Edward Tenthoff's trades and holding each position for 2 Years would result in 81.82% of your transactions generating a profit, with an average return of +99.16% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
CAPR Analyst Recommendation Trends
Rating
Feb 26
Mar 26
Apr 26
May 26
Jun 26
Strong Buy
12
10
7
17
12
Buy
2
4
5
8
4
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
14
14
12
25
16
Each month's total comprises the sum of three months' worth of ratings.
CAPR Financial Forecast
CAPR Stock Forecast FAQ
What is CAPR’s average 12-month price target, according to analysts?
Based on analyst ratings, Capricor Therapeutics, Inc.’s 12-month average price target is 53.00.
What is CAPR’s upside potential, based on the analysts’ average price target?
Capricor Therapeutics, Inc. has 52.74% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is CAPR a Buy, Sell or Hold?
Capricor Therapeutics, Inc. has a consensus rating of Strong Buy which is based on 8 buy ratings, 0 hold ratings and 0 sell ratings.
What is Capricor Therapeutics, Inc.’s price target?
The average price target for Capricor Therapeutics, Inc. is 53.00. This is based on 8 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $62.00 ,the lowest forecast is $38.00. The average price target represents 52.74% Increase from the current price of $34.7.
The highest analyst price target is $62.00 ,the lowest forecast is $38.00. The average price target represents 52.74% Increase from the current price of $34.7.
What do analysts say about Capricor Therapeutics, Inc.?
Capricor Therapeutics, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 8 Wall Streets Analysts.
How can I buy shares of CAPR?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.